Loading clinical trials...
Loading clinical trials...
Tolerability and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers With Existing Botulinum Immunity
Conditions
Interventions
rBV A/B
Locations
2
United States
California Department of Public Health
Richmond, California, United States
Battelle Biomedical Research Center
West Jefferson, Ohio, United States
Start Date
July 9, 2024
Primary Completion Date
June 2, 2025
Completion Date
June 2, 2025
Last Updated
June 13, 2025
Lead Sponsor
California Department of Public Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions